Recent Recurrent Melanoma News

Targeted Therapy Nivolumab Outperforms Chemotherapy in Advanced Melanoma (October 13, 2014)

Nivolumab appears to be more active and safer than chemotherapy in patients with advanced melanoma who have received previous treatment. These findings were presented at the 2014 European Society for Medical... Continue Reading

COMBI-v BRAF/MEK Inhibitor Combination Trial Impressive in Melanoma (October 8, 2014)

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology Meeting this week. Of the... Continue Reading

BRAF/MEK Inhibitor Combination Impressive in Melanoma Trials (October 2, 2014)

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology Meeting this week. Of the... Continue Reading

Pembrolizumab Gets FDA Approval in Advanced Melanoma (September 5, 2014)

The U.S. Food & Drug Administration (FDA) has granted approval to Merck’s new immunotherapy drug, Keytruda (pembrolizumab), for treating metastatic melanoma.   It is the first anti-PD-1 drug,... Continue Reading

Largest Study to Date of Pembrolizumab in Advanced Melanoma Shows Promising Activity (July 31, 2014)

The investigational anti-PD-1 antibody pembrolizumab is demonstrating promising survival rates among patients with advanced melanoma. Data from an ongoing Phase 1 trial of the drug were presented at the... Continue Reading

Investigational Drug Pembrolizumab Shows Anticancer Activity in Advanced Melanoma (July 30, 2014)

Recent findings reported in The Lancet indicate that the investigational drug pembrolizumab may be effective in patients with advanced melanoma that has progressed after treatment with Yervoy® (ipilimumab).[1]... Continue Reading

Trial Evaluating Nivolumab in Advanced Melanoma Halted Early Because of Superior Results (July 8, 2014)

Bristol-Myers Squibb announced on Tuesday that its clinical trial evaluating cancer immunotherapy nivolumab, which is being developed in advanced melanoma was halted early after it was determined that... Continue Reading

Enzyme Inhibitor Combined with Yervoy Is Well Tolerated and Shows Tumor Response in Metastatic Melanoma Patients (June 4, 2014)

In a phase 1/2 study presented at the 2014 ASCO meeting, researchers determined a dosing level of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor combined with Yervoy® (ipilimumab) that was well tolerated... Continue Reading

T-VEC Vaccine Promotes Tumor Shrinkage in Advanced Melanoma (March 28, 2014)

The experimental cancer vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage and triggered a systemic immune response in patients with advanced melanoma, according to the results of a study... Continue Reading

Nivolumab Produces Durable Responses in Advanced Melanoma (March 14, 2014)

Nivolumab, an investigational, anti–PD-1 drug, produced durable responses in patients with advanced melanoma, according to the results of a study published in the Journal of Clinical Oncology. Of the... Continue Reading

Next Page »